Cadrenal Therapeutics Inc. reported results from a randomized, blinded, placebo-controlled Phase 2 trial of CAD-1005 (formerly VLX-1005), a selective 12-lipoxygenase inhibitor, in patients with heparin-induced thrombocytopenia receiving standard anticoagulant therapy. The study did not meet its primary endpoint of platelet count recovery, which was similar between CAD-1005 and placebo. As a key secondary endpoint, the incidence of new or worsening thrombotic events was 50% in the CAD-1005 arm versus more than 75% in the placebo arm; the trial was not powered for statistical significance. The company said detailed trial results will be presented at a future scientific meeting and that an End-of-Phase 2 FDA meeting is scheduled for March 2026 to discuss a Phase 3 path.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240830PRIMZONEFULLFEED9659758) on February 24, 2026, and is solely responsible for the information contained therein.